← Records

BONAVENTURA v. BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.

E.D. Pa. · No. 2:26-cv-05649

Full docket on CourtListener ↗

No federal docket timeline hydrated for this case yet (state-court settlements have no RECAP docket).

Our records for this case (1)

MatterTypePractice areaCourtDateValue
BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.source ↗
filed by Keller Postman LLC · Judge Mary Kay Costello · No. 2:26-cv-05649 · 28:1332 Diversity-Product Liability · view case timeline →
Comparable settlements $30M–$725M ▾
Comparable rulings split: Bayhealth confirmed a confidentiality duty for health-data disclosure while Integris and LabCorp left key theories 'unclear,' and Gunnar Optiks shows tracking-tech claims often survive early dismissal only on fact-intensive grounds.
Comparable settlements $30M–$725M median $59.50M · n=10
Meta $725M · Google $68M · Google Assistant $68M
Per member (realized): ~$30 median · $29–$30 (n=2)
Comparable verdict: Google LLC $425.70M · Google LLC $425M
Class (from complaint): Purchasers and payors of Combivent Respimat and Spiriva Respimat inhalation sprays on behalf of themselves and others similarly situated.
Key precedent: Doe v. Bayhealth Medical Ctr. — health-provider tracking-tech disclosure claim survived MTD, closest analog to pharma-related data sharing.
Main risk: Dismissal on standing/causation grounds as in LabCorp (loss causation) or removal/jurisdictional dismissal as in Integris
This defendant: Six separate Privacy & Wiretap filings against Boehringer Ingelheim suggest coordinated multidistrict-style consumer litigation, raising settlement pressure.
Rough EV model (wide — class size is the big unknown, not a prediction): $9M–$70M
Theory label (Privacy & Wiretap) mismatches class definition (drug purchasers/payors), so per-member and class-size anchors are extrapolated, not directly matched. · grounded in 6 rulings, 10 settlements, 2 verdicts
FilingPrivacy & WiretapE.D. Pa.2026-08-07$30M–$725M
comparable settlements